Lixte Biotechnology Holdings Equity Warrants Exp 1st Jan 2025 LIXTW:NASDAQ

RT Quote | USD
Last | 04/18/24 EDT
0.0532UNCH (UNCH)
Volume
45
52 week range
0.03 - 0.14
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0532
  • 52 Week High0.14
  • 52 Week High Date07/17/23
  • 52 Week Low0.03
  • 52 Week Low Date02/07/24

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0532
  • 52 Week High0.14
  • 52 Week High Date07/17/23
  • 52 Week Low0.03
  • 52 Week Low Date02/07/24
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lixte Biotechnology Holdings Equity Warrants Exp 1st Jan 2025

 

Profile

MORE
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have...
Bastiaan Van Der Baan
Chairman of the Board, President, Chief Executive Officer
Eric Forman J.D.
Chief Operating Officer, Vice President
Robert Weingarten
Chief Financial Officer, Vice President
Address
No. 2, 248 Route 25A
East Setauket, NY
11733
United States
https://lixte.com/